NCT06369285Phase 2Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Study sponsor: Puma Biotechnology, Inc. · PBYI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12-30Estimated
Enrollment · participants225Estimated
Source updated2026-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 75 participants

Before: 150 participants (planned). After: 225 participants (planned).

Primary completion date changed

Before: 30 Jun 2027. After: 30 Dec 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview